National Health (Originator Brand) Amendment Determination 2018 (No. 3) (PB 44 of 2018) (Cth)

PB 44 of 2018

National Health (Originator Brand) Amendment Determination 2018 (No. 3)

National Health Act 1953

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated       29 May 2018

______________________________________

LISA LA RANCE

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2018 (No. 3).

(2)     This Determination may also be cited as PB 44 of 2018.

1. Commencement

This Determination commences on 1 June 2018.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1 (table item 1)

Repeal the items, substitute:

1	Abacavir with Lamivudine	Kivexa
1A	Abatacept	Orencia Orencia Clickject
1B	Acamprosate	Campral
1C	Acarbose	Glucobay 50 Glucobay 100
1D	Aciclovir	Zovirax Zovirax 200 mg Zovirax 800 mg

[2]   Schedule 1 (after table item 3)

insert:

3A Adrenaline EpiPen EpiPen Jr.

[3]       Schedule 1 (after table item 28A)

insert:

28B	Buprenorphine	Subutex	Sublingual
Norspan	Transdermal

[4]       Schedule 1 (after table item 68)

omit:

68A Ganciclovir Cymevene

[5]   Schedule 1 (table item 74)

Repeal the items, substitute:

74	Enalapril with Hydrochlorothiazide	Renitec Plus 20/6
74A	Enoxaparin	Clexane
74B	Entecavir	Baraclude
74C	Eplerenone	Inspra

[5]   Schedule 1 (after table item 79)

insert:

79A Everolimus Afinitor Certican

[6]   Schedule 1 (after table item 80)

insert:

80A	Ezetimibe	Ezetrol
80B	Ezetimibe and rosuvastatin	Rosuzet Composite Pack
80C	Ezetimibe with simvastatin	Vytorin

[7]   Schedule 1 (after table item 96)

insert:

96A Ganciclovir Cymevene

[8]   Schedule 1 (after table item 135)

insert:

135A Lincomycin Lincocin

[9]   Schedule 1 (after table item 156)

insert:

156A Moxonidine Physiotens